Mazdutide news and clinical trials

A systematic review and meta-analysis of three randomized controlled trials found that mazdutide led to greater reductions in HbA1c and body weight compared to dulaglutide in adults with type 2 diabetes. Mazdutide was associated with higher rates of gastrointestinal side effects.

A review published in the Journal of Diabetes and Metabolic Disorders analyzed the progress and challenges in developing pediatric anti-obesity medications. It emphasized the need to verify the safety and efficacy of GLP-1 agonists and multi-target drugs like mazdutide through pediatric trials.

A study published in Diabetes, Obesity & Metabolism found that the dual GLP-1R/GCGR agonist mazdutide decreased circulating cholesterol levels and attenuated liver steatosis in mice with metabolic dysfunction-associated steatotic liver disease.

A narrative review published in Obesity Reviews examines the role of dual glucagon and GLP-1 receptor agonists in treating obesity and metabolic dysfunction-associated steatohepatitis. The review highlights that mazdutide and survodutide show potent weight-loss and antihyperglycemic effects.

New paper in Diabetes, obesity & metabolism: Efficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis.

Fujian Shengdi Pharmaceutical Co., Ltd. registered a Phase 2 trial for 240 participants to evaluate the efficacy and safety of HRS-4729 injection in patients with type 2 diabetes who failed to achieve glycemic control on diet, exercise, or stable metformin.

Shanghai Zhongshan Hospital completed a Phase 1/2 trial involving 43 obese female adults with polycystic ovary syndrome. The study evaluated the efficacy of 24 weeks of weekly mazdutide treatment on lowering the free androgen index.

A cross-sectional analysis of 128 videos regarding GLP-1 receptor agonists on Chinese platforms found that Bilibili provided higher quality information than Douyin. The study warned that Douyin remains a significant risk environment for misinformation and the promotion of fraudulent products.

Hongwei Jiang registered a 30-participant phase 4 clinical trial for Mazdutide in adults with obesity and gout. The study will evaluate the effect of the drug on annualized gout flare rates over 52 weeks.

Tongji Hospital registered a randomized controlled trial for 194 overweight or obese adults to evaluate the efficacy of mazdutide versus placebo on fatty pancreas. The primary endpoint is the change in pancreatic proton density fat fraction measured by MRI at week 48.

A network meta-analysis of 58 randomized controlled trials with 24 214 participants compared weight loss efficacy across GLP-1 based drugs. Retatrutide showed the greatest weight loss at -22.10%, and mazdutide demonstrated better tolerability compared to other agents.

The Second Affiliated Hospital of Chongqing Medical University registered an exploratory trial to test if Mazdutide can safely reduce portal pressure in 50 overweight patients with compensated cirrhosis and clinically significant portal hypertension.

Tongji Hospital registered a phase 2 trial to evaluate the efficacy of Mazdutide combined with a levonorgestrel-releasing intrauterine system for fertility-sparing treatment in 128 obese or overweight patients with atypical endometrial hyperplasia or early-stage cancer.

New randomized trial in The lancet. Diabetes & endocrinology: Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial.

Huijie Zhang registered a phase 4 trial to enroll 820 participants with type 2 diabetic kidney disease. The study will test whether combining triple or quadruple therapies involving empagliflozin, finerenone, and mazdutide reduces the urine albumin-to-creatinine ratio.

Yanbing Li registered a multicentre, double-blind, randomized, placebo-controlled trial to investigate the efficacy of Mazdutide for diabetes remission in 249 Chinese type 2 diabetes patients. Participants will be those with poor glycemic control on current standard therapies.

Researchers developed and validated a multiplexed LC-HRMS method to identify and quantify nine different GLP-1 receptor agonists. The new method achieved baseline separation for most peptides within a 20-minute runtime and demonstrated good linearity.

Researchers published a study identifying a renoprotective role for tubular glucagon receptor signaling in diabetic kidney disease. Their experiments in mouse models showed that genetic ablation of this receptor exacerbates kidney injury, while re-expression restores function.

A narrative review published in the Journal of the American Heart Association summarizes the cardiovascular effects of dual glucagon and GLP-1 receptor agonists. Clinical data suggest these drugs increase heart rate to a similar extent as GLP-1 monoagonists while reducing blood pressure.

West China Hospital registered a Phase 4 trial for 60 living liver donors to compare 12 weeks of mazdutide plus lifestyle optimization versus placebo for reducing hepatic steatosis before surgery.

Tianjin Medical University registered a randomized controlled trial to evaluate the safety and efficacy of switching to Mazdutide in 72 type 2 diabetes patients with moderate to severe nonalcoholic fatty liver disease who previously used semaglutide.

New systematic review in BMJ (Clinical research ed.): Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.

A meta-analysis published in Diabetes, Obesity & Metabolism assessed the effects of mazdutide in Chinese adults with obesity or type 2 diabetes. The review found that mazdutide was associated with dose-dependent reductions in body weight and HbA1c compared to placebo.

The China National Center for Cardiovascular Diseases registered a Phase 4 trial for 116 participants to evaluate the effect of mazdutide on coronary plaque progression in patients with coronary atherosclerosis and overweight or obesity.

Shandong Provincial Hospital registered a phase 4 trial to determine if Mazdutide can return 150 adults with prediabetes to normal blood sugar levels. Participants will receive either 4 mg or 6 mg doses of the drug or a placebo over 24 weeks.

The China-Japan Friendship Hospital registered a trial investigating bariatric surgery combined with GLP-1 receptor agonist therapy in 200 Chinese patients with obesity. The research aims to evaluate the efficacy and safety of this adjuvant therapy for postoperative weight management.

A phase 3 clinical trial involving 461 participants found that 9-mg doses of mazdutide resulted in a -16.65% mean body weight reduction at week 60 compared to -1.50% in the placebo group. The most common adverse events were vomiting, nausea, and diarrhea.

A JAMA article summarized research on the use of a 9-mg dose of mazdutide for weight reduction in Chinese adults with obesity.

A JAMA journal article provided new evidence on the use of mazdutide and orforglipron for the treatment of obesity and diabetes.

A Lancet Diabetes & Endocrinology review synthesized evidence from clinical trials on various obesity medications, including GLP-1 receptor agonists and newer multiagonists. The review found these therapies offer weight loss-independent benefits for various comorbid conditions.

Eli Lilly and Company completed a phase 2 proof-of-concept study of 308 participants to evaluate the effect of Mazdutide on alcohol use disorder. The study concluded on May 19, 2026.

Eli Lilly and Company completed a phase 2 study in 179 adult participants investigating the efficacy and safety of mazdutide compared to placebo for weight management. Results for this trial were posted on April 21, 2026.

Shanghai Zhongshan Hospital registered a randomized controlled trial for 420 participants to evaluate the effectiveness of intensive lifestyle interventions, a reduced dose of 3.0 mg mazdutide once weekly, or their combination for long-term weight maintenance.

A review of obesity pharmacotherapy indicates a shift toward multi-receptor agonists and personalized treatment strategies. Emerging therapies such as retatrutide and oral amylin analogs show promise in achieving significant weight loss and improving metabolic outcomes.

A study published in Pharmaceuticals found that mazdutide treatment alleviated hepatic endoplasmic reticulum stress and improved lipid metabolism in mouse and cellular models of metabolic dysfunction-associated steatotic liver disease. These effects reduced liver injury and hepatic steatosis.

A randomized phase 2 trial published in Med found that 9 mg of the dual agonist mazdutide led to a mean weight reduction of -12.78% in Chinese adults without diabetes after 24 weeks. Participants receiving mazdutide showed significant weight loss compared to 1.80% for the placebo group.

Innovent Biologics registered a multicenter, double-blind, phase 3 study to evaluate the efficacy and safety of IBI362 in 336 patients with mild to moderate hypertension and obesity or overweight who have not received prior antihypertensive treatment.

A review published in Expert Opinion on Therapeutic Patents analyzed 12 patent families for the GLP-1 and glucagon receptor agonist mazdutide. The study highlights how Innovent Biologics utilized layered patent strategies covering formulation and clinical use to establish long-term exclusivity.

A meta-analysis of five randomized controlled trials found that mazdutide significantly reduced body weight, waist circumference, and blood pressure in non-diabetic adults with obesity. The drug was associated with mild to moderate adverse events.

New review in Endocrinology, diabetes & metabolism: Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials.

A study published in Diabetes, Metabolic Syndrome and Obesity performed a clinical evaluation of five long-acting GLP-1 receptor agonists in China. Researchers gave semaglutide and dulaglutide the highest scores, while mazdutide was not currently recommended due to high costs and limited evidence.

A systematic review and meta-analysis published in Cardiology in Review examined 10 randomized trials involving 3236 participants and found that incretin-based dual and triple agonists significantly reduced body weight and waist circumference. These agents showed an increased risk of adverse events.

Hangzhou Zhongmei Huadong Pharmaceutical registered a phase 3 trial to compare the efficacy and safety of HDM1005 versus mazdutide in 912 subjects with type 2 diabetes who have inadequate glycemic control on metformin alone or combined with an SGLT2 inhibitor.

Innovent Biologics completed a phase 3 study comparing IBI362 6 mg and semaglutide 1 mg in 349 Chinese adults with obesity and early type 2 diabetes. The trial evaluated weight loss efficacy and safety over a 32-week treatment period followed by an extension phase.

Researchers reviewed current and emerging intervention strategies for hyperuricemia, including Western medicines and Traditional Chinese Medicine. The study highlights the mechanism of action for various treatments, including the GLP-1/GCG dual-receptor agonist mazdutide, as an emerging therapy.

A review published in Pharmacological Research examined mechanisms by which glucagon receptor agonists, such as survodutide, cotadutide, and mazdutide, reduce body weight. The authors noted that evidence for these processes in humans is currently limited and relies heavily on preclinical data.

A phase 3 trial published in Nature found that 24 weeks of mazdutide monotherapy significantly improved glycemic control and weight loss in Chinese adults with type 2 diabetes. Participants receiving 6 mg of mazdutide experienced -7.81% weight loss versus -1.26% for the placebo group.

A phase III trial of 731 participants found that 28 weeks of treatment with 4 mg or 6 mg mazdutide provided superior reductions in HbA1c and body weight compared to 1.5 mg dulaglutide in Chinese adults with type 2 diabetes.

A review in The Lancet Diabetes & Endocrinology notes that five GLP-1 receptor agonists including liraglutide, beinaglutide, semaglutide, tirzepatide, and mazdutide have been approved in China for weight management since 2021, broadening therapeutic choices for obesity care.

Innovent Biologics registered a phase 3 study to assess the efficacy and safety of IBI362 in 180 Chinese adolescents aged 12 to 18 years with obesity or overweight. The trial targets participants who did not achieve a 5 kg weight reduction through diet and exercise.